P682: NEMTABRUTINIB (MK-1026), A NON-COVALENT INHIBITOR OF WILD-TYPE AND C481S MUTATED BRUTON TYROSINE KINASE FOR B-CELL MALIGNANCIES: EFFICACY AND SAFETY OF THE PHASE 2 DOSE-EXPANSION BELLWAVE-001 STUDY

• J. Woyach,
• I. W. Flinn,
• F. T. Awan,
• H. Eradat,
• D. Brander,
• M. Tees,
• S. A. Parikh,
• T. Phillips,
• W. Wang,
• N. M. Reddy,
• M. Z. Farooqui,
• J. C. Byrd,
• D. M. Stephens

Affiliations

J. Woyach

1 Division of Hematology, The Ohio State University, Columbus, Columbus

I. W. Flinn

2 Sarah Cannon Center Research Institute, Nashville, Nashville

F. T. Awan

3 Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas

H. Eradat

4 Department of Hematology-Oncology, David Geffen School of Medicine at UCLA, Los Angeles

D. Brander

5 Duke Cancer Institute, Duke University Medical Center, Durham

M. Tees

6 Colorado Blood Cancer Institute, Denver

S. A. Parikh

7 Division of Hematology, Mayo Clinic, Rochester

T. Phillips

8 Division of Hematology and Oncology, University of Michigan Rogel Cancer Center, Ann Arbor

W. Wang

9 Veristat, LLC, Southborough

N. M. Reddy

10 Merck & Co., Inc., Kenilworth

M. Z. Farooqui

10 Merck & Co., Inc., Kenilworth

J. C. Byrd

11 Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati

D. M. Stephens

12 Division of Hematology and Hematologic Malignancies, University of Utah Huntsman Cancer Institute, Salt Lake City, United States of America